Retinoids and Differentiation of Normal and Malignant Hematopoietic Cells
暂无分享,去创建一个
[1] P. Fenaux,et al. Retinoic Acid Syndrome , 1998, Drug safety.
[2] S. Corey,et al. Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid , 1997, Leukemia.
[3] A. Zelent,et al. RaRα1/RARα2-PML mRNA expression in acute promyelocytic leukemia cells : A molecular and laboratory-clinical correlative study , 1997 .
[4] Mi-Ock Lee,et al. Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP‐TF and their heterodimerization , 1997, The EMBO journal.
[5] C. Glass,et al. Nuclear receptor coactivators. , 1997, Current opinion in cell biology.
[6] D. Mangelsdorf,et al. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. , 1997, Genes & development.
[7] G. Duester. Involvement of Alcohol Dehydrogenase, Short-Chain Dehydrogenase/Reductase, Aldehyde Dehydrogenase, and Cytochrome P450 in the Control of Retinoid Signaling by Activation of Retinoic Acid Synthesis† , 1996 .
[8] Jacek Ostrowski,et al. Two distinct actions of retinoid-receptor ligands , 1996, Nature.
[9] E. Wattel,et al. All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. , 1996, Leukemia.
[10] J. L. Napoli. Retinoic acid biosynthesis and metabolism , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] P. Chambon. A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] K. Shudo,et al. Successful Treatment of Relapse of Acute Promyelocytic Leukemia with a New Synthetic Retinoid, Am80 , 1996, Annals of Internal Medicine.
[13] R. Speich,et al. Sweet's syndrome involoving the musculoskeletal system during treatment of promyelocytic leukemia with all-trans retinoic acid. , 1996, Leukemia.
[14] E. Smeland,et al. The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34+ erythroid progenitor cells. , 1996, Blood.
[15] S. Corey,et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.
[16] Philippe Kastner,et al. Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.
[17] R. Evans,et al. The RXR heterodimers and orphan receptors , 1995, Cell.
[18] P. Fenaux,et al. In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. , 1995, Leukemia.
[19] H. Tsuda,et al. Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid. , 1995, International journal of hematology.
[20] P. Fenaux,et al. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Stunnenberg,et al. 9-cis retinoic acid signaling: changing partners causes some excitement. , 1995, Genes & development.
[22] M. Gaub,et al. Characterization of nuclear retinoic acid binding activity in sensitive leukemic cell lines: cell specific uptake of ATRA and RAR alpha protein modulation. , 1995, Biochemical and Biophysical Research Communications - BBRC.
[23] P. Chambon,et al. Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. , 1995, Molecular endocrinology.
[24] R. Warrell,et al. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. , 1995, Blood.
[25] M. Donovan,et al. The cellular retinoic acid binding proteins , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[26] K. Umesono,et al. Unique response pathways are established by allosteric interactions among nuclear hormone receptors , 1995, Cell.
[27] H. Dombret,et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. , 1995, Blood.
[28] K. Umesono,et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. , 1995, Genes & development.
[29] J. Wiley,et al. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. , 1995, Leukemia.
[30] T. Perlmann,et al. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. , 1995, Genes & development.
[31] J. Gustafsson,et al. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[32] A. Zelenetz,et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). , 1995, Blood.
[33] C. Chastang,et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group. , 1995, Leukemia & lymphoma.
[34] S. Nagpal,et al. Separation of Transactivation and AP1 Antagonism Functions of Retinoic Acid Receptor (*) , 1995, The Journal of Biological Chemistry.
[35] P. Emanuel,et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. , 1994, The New England journal of medicine.
[36] T. Rabbitts,et al. Chromosomal translocations in human cancer , 1994, Nature.
[37] M. Toubert,et al. Induction of high-affinity GM-CSF receptors during all-trans retinoic acid treatment of acute promyelocytic leukemia. , 1994, Leukemia.
[38] P. Fenaux,et al. Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. , 1994, Leukemia.
[39] G. Zauli,et al. All-trans retinoic acid and induction of apoptosis in acute promyelocytic leukemia cells. , 1994, Leukemia & lymphoma.
[40] M. Fey,et al. Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group [letter] , 1994 .
[41] M. Fey,et al. Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group. , 1994, Blood.
[42] R. Gallagher,et al. Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-alpha. , 1994, Blood.
[43] P Chambon,et al. The retinoid signaling pathway: molecular and genetic analyses. , 1994, Seminars in cell biology.
[44] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[45] N. Stuurman,et al. The t(15;17) translocation alters a nuclear body in a retinoic acid‐reversible fashion. , 1994, The EMBO journal.
[46] A. Zelent. TRANSLOCATION OF THE RARα LOCUS TO THE PML OR PLZF GENE IN ACUTE PROMYELOCYTIC LEUKAEMIA , 1994 .
[47] E. Dmitrovsky,et al. All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study , 1994, Annals of Internal Medicine.
[48] V. Giguère. Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. , 1994, Endocrine reviews.
[49] A. Zelent,et al. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[50] A. Dejean,et al. The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells , 1994 .
[51] P. Martiat,et al. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. , 1994, Leukemia.
[52] R. Evans,et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein , 1994, Cell.
[53] Maria Carmo-Fonseca,et al. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells , 1994, Cell.
[54] N. Komatsu,et al. Acute promyelocytic leukaemia, tretinoin, and granulocyte colony-stimulating factor , 1994, The Lancet.
[55] H. Koeffler,et al. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-alpha and retinoid X receptor-alpha RNA by HL-60 cells. , 1993, Blood.
[56] J. Pike,et al. Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. , 1993, The Journal of biological chemistry.
[57] H. Tilly,et al. Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia , 1993 .
[58] R. Krance,et al. Tretinoin toxicity in children with acute promyelocytic leukaemia , 1993, The Lancet.
[59] M. Kris,et al. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. , 1993, Journal of the National Cancer Institute.
[60] P. Fenaux,et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .
[61] T. Naoe,et al. Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia , 1993 .
[62] M. Villalona-Calero,et al. Acute progranulocytic leukemia (APL): possible in vivo differentiation by granulocyte colony-stimulating factor (G-CSF) , 1993, Leukemia.
[63] P. Fenaux,et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. , 1993, Blood.
[64] H. de Thé,et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. , 1993, Blood.
[65] P. Pelicci,et al. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein. , 1993, Blood.
[66] Myriam Alcalay,et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells , 1993, Cell.
[67] P. Chambon,et al. PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. , 1993, The EMBO journal.
[68] C. Chomienne,et al. Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. , 1993, Leukemia.
[69] R. Warrell,et al. Acute promyelocytic leukemia. , 1993, The New England journal of medicine.
[70] Xiao-Kun Zhang,et al. Regulation of retinoid and thyroid hormone action through homodimeric and heterodimeric receptors , 1993, Trends in Endocrinology & Metabolism.
[71] R. Berger,et al. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. , 1993, The Journal of clinical investigation.
[72] R. Berger,et al. A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. , 1992, Leukemia.
[73] R. Evans,et al. A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. , 1992, Genes & development.
[74] A. Näär,et al. Transcriptional regulation by the nuclear receptor superfamily. , 1992, Current opinion in biotechnology.
[75] H. Dombret,et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. , 1992, Blood.
[76] K. Robertson,et al. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. , 1992, Blood.
[77] J. L. Napoli,et al. Biosynthesis of all-trans-retinoic acid from retinal. Recognition of retinal bound to cellular retinol binding protein (type I) as substrate by a purified cytosolic dehydrogenase. , 1992, The Journal of biological chemistry.
[78] R. Warrell,et al. The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia , 1992, Annals of Internal Medicine.
[79] T. Naoe,et al. Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone. , 1992, Leukemia.
[80] C. Chomienne,et al. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. , 1992, Cancer research.
[81] R. Warrell,et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1992, Cancer research.
[82] F. Lo Coco,et al. Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. , 1992, The EMBO journal.
[83] P. Chambon,et al. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. , 1992, The EMBO journal.
[84] L. Deaven,et al. Characterization of a fusion cDNA (RARA/myl) transcribed from the t(15;17) translocation breakpoint in acute promyelocytic leukemia , 1992, Molecular and cellular biology.
[85] M. Pfahl,et al. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors , 1992, Nature.
[86] Gregor Eichele,et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.
[87] J. Grippo,et al. 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα , 1992, Nature.
[88] E. Dmitrovsky,et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. , 1992, Blood.
[89] A. Agadir,et al. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1991, Leukemia.
[90] H. de Thé,et al. All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. , 1991, The Journal of clinical investigation.
[91] P. Freemont,et al. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. , 1991, Science.
[92] J. Samarut,et al. A novel mechanism of action for v-ErbA: Abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors , 1991, Cell.
[93] J. L. Napoli,et al. Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli. Characterization and evidence that holo-CRABP is a substrate in retinoic acid metabolism. , 1991, The Journal of biological chemistry.
[94] Christine Chomienne,et al. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.
[95] K. Umesono,et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML , 1991, Cell.
[96] P. Pelicci,et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. , 1991, Oncogene.
[97] J. L. Napoli,et al. Holocellular retinol binding protein as a substrate for microsomal retinal synthesis. , 1991, Biochemistry.
[98] E. Dmitrovsky,et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.
[99] P. Pandolfi,et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[100] R Berger,et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.
[101] H. Dombret,et al. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid , 1990, The Lancet.
[102] R Berger,et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.
[103] Christine Chomienne,et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.
[104] D. Sheer,et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. , 1990, Science.
[105] S. Collins,et al. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha) , 1990, Molecular and cellular biology.
[106] T G Cotter,et al. HL‐60 cells induced to differentiate towards neutrophils subsequently die via apoptosis , 1990, Clinical and experimental immunology.
[107] J. Testa. Chromosome translocations in human cancer. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[108] M. K. Armstrong,et al. Cellular lipid binding proteins: expression, function, and nutritional regulation 1 , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[109] R. Berger,et al. RETINOIC ACID THERAPY FOR PROMYELOCYTIC LEUKAEMIA , 1989, The Lancet.
[110] W. Blaner. Retinol-binding protein: the serum transport protein for vitamin A. , 1989, Endocrine reviews.
[111] O. Gandrillon,et al. Expression of the v-erbA product, an altered nuclear hormone receptor, is sufficient to transform erythrocytic cells in vitro , 1989, Cell.
[112] R. Kurzrock,et al. Malignancy-associated Sweet's syndrome: review of the world literature. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] Zhen-yi Wang,et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.
[114] Z. Wang,et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. , 1987, Chinese medical journal.
[115] A. Tobler,et al. Retinoids. Structure-function relationship in normal and leukemic hematopoiesis in vitro. , 1986, The Journal of clinical investigation.
[116] Koeffler Hp. Human acute myeloid leukemia lines: models of leukemogenesis. , 1986 .
[117] J. Fontana,et al. The role of 13 cis‐retinoic acid in the remission induction of a patient with acute promyelocytic leukemia , 1986, Cancer.
[118] J. Rowley,et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. , 1984, The American journal of medicine.
[119] H. Koeffler,et al. Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. , 1982, Experimental cell research.
[120] S. Collins,et al. Terminal Differentiation of Human Promyelocytic Leukemic Cells in Primary Culture in Response to Retinoic Acid , 1981 .
[121] R. Lotan,et al. Retinoic acid-induced modifications in the growth and cell surface components of a human carcinoma (HeLa) cell line. , 1980, Experimental cell research.
[122] S. Collins,et al. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[123] H. Gralnick,et al. A variant form of hypergranular promyelocytic leukemia (M3) , 1980, Annals of internal medicine.
[124] L. Ellman,et al. Acute promyelocytic leukemia , 1979, American journal of hematology.
[125] L. Sachs. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia , 1978, Nature.
[126] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[127] R. Sweet. AN ACUTE FEBRILE NEUTROPHTLIC DERMATOSTS. , 1964 .
[128] P. Fenaux,et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. , 1990, Blood.
[129] L. Nagy,et al. Retinoid-induced apoptosis in normal and neoplastic tissues , 1998, Cell Death and Differentiation.
[130] E. Estey,et al. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia , 1997, Leukemia.
[131] A. Baruchel,et al. Chronic myelomonocytic leukemia: from biology to therapy. , 1997, Hematology and cell therapy.
[132] H. Dombret,et al. All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. , 1996, Leukemia.
[133] A. Notario,et al. Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease. , 1996, Haematologica.
[134] P. Rousselot,et al. Récepteurs nucléaires et ontogénèse du tissu hématopoïétique. , 1995 .
[135] P. Maslak,et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. , 1994, Leukemia.
[136] H. Snoeck,et al. Effect of retinoic acid (RA) on myeloid progenitors in normal bone marrow (BM) , 1994, Leukemia.
[137] P. Fenaux,et al. Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. , 1994, Blood.
[138] C. Chomienne,et al. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. , 1994, Leukemia.
[139] P. Pandolfi,et al. Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.
[140] L. Sachs,et al. 45. Regulation of BcI-2 and cell death by all-trans retinoic acid in acute promyelocytic leukemic cells , 1992 .
[141] Z. Wang,et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. , 1990, Nouvelle revue francaise d'hematologie.
[142] J. Abita,et al. Inefficacy of the synthetic aromatic retinoid etretinate and of its free acid on the in-vitro differentiation of leukemic cells. , 1986, Leukemia research.
[143] J. Abita,et al. Structure-activity relationships of aromatic retinoids on the differentiation of the human histiocytic lymphoma cell line U-937. , 1986, Leukemia research.
[144] A. Kalamkarian,et al. [Sweet's syndrome (acute febrile neutrophilic dermatosis)]. , 1985, Vestnik dermatologii i venerologii.